Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Payables (2016 - 2025)

ImmunityBio (IBRX) has disclosed Payables for 12 consecutive years, with $46.8 million as the latest value for Q4 2025.

  • Quarterly Payables rose 15.42% to $46.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $46.8 million through Dec 2025, up 15.42% year-over-year, with the annual reading at $46.8 million for FY2025, 15.42% up from the prior year.
  • Payables for Q4 2025 was $46.8 million at ImmunityBio, up from $43.6 million in the prior quarter.
  • The five-year high for Payables was $544.2 million in Q2 2023, with the low at $44000.0 in Q2 2024.
  • Average Payables over 5 years is $148.4 million, with a median of $43.2 million recorded in 2023.
  • The sharpest move saw Payables plummeted 99.99% in 2024, then surged 81047.73% in 2025.
  • Over 5 years, Payables stood at $303.2 million in 2021, then surged by 56.25% to $473.7 million in 2022, then plummeted by 90.98% to $42.7 million in 2023, then fell by 4.98% to $40.6 million in 2024, then rose by 15.42% to $46.8 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $46.8 million, $43.6 million, and $35.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.